Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-M-R II at Mumps Expiry Potency in Children
NCT00092391Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 1999
- Primary completion
- Jul 2001
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, double-blind trial of M-M-R II in measles, mumps and rubella (3 arms), sponsored by Merck & Co. Primary endpoint: Neutralizing antibodies to mumps at 6 weeks postvaccination. Started Feb 1999; status: completed.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NCT00092391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092391.